| Recruiting | A Study of Lorigerlimab in Participants With Advanced Solid Tumors NCT06730347 | MacroGenics | Phase 2 |
| Withdrawn | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer NCT05672095 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer NCT06867562 | Jina Pharmaceuticals Inc. | Phase 3 |
| Recruiting | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048 | Mayo Clinic | Phase 1 |
| Recruiting | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Ca NCT05538091 | Ronald Buckanovich | Phase 2 |
| Recruiting | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer NCT05465941 | Mayo Clinic | Phase 2 |
| Completed | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers NCT05483933 | Shattuck Labs, Inc. | Phase 1 |
| Recruiting | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Peg NCT05271318 | TILT Biotherapeutics Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopia NCT04781088 | Floor Backes, MD | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, NCT04753216 | Northwestern University | Phase 2 |
| Unknown | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) NCT04678102 | Seoul National University Hospital | Phase 1 |
| Terminated | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies NCT04244552 | Atreca, Inc. | Phase 1 |
| Recruiting | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649 | Ira Winer | Phase 2 |
| Terminated | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, o NCT04019288 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527 | Precigen, Inc | Phase 1 |
| Terminated | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen i NCT03691376 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube NCT03587311 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT03206047 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, NCT03026062 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713 | Mayo Clinic | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |